Gain Therapeutics, Inc. (GANX)
Nasdaq · Healthcare · Biotechnology
$1.69−1.17%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $73.8M
- 52-week range
- $1.53 – $4.34
- 52-week change
- −15.35%
- EPS (trailing)
- −$0.50
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Net income
- −$20.2M
- Diluted EPS
- −$0.61
From the company’s annual report on SEC EDGAR.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Headquarters: Bethesda, United States · 20 employees · gaintherapeutics.com